The mothers, Omega-3 and mental health study

BMC Pregnancy and Childbirth

Volumn 11, Issue , 2011, Pages

  Mozurkewich, Ellen ^a   Chilimigras, Julie ^a   Klemens, Chelsea ^b   Keeton, Kristie ^c   Allbaugh, Lucy ^d   Hamilton, Susan ^d   Berman, Deborah ^a   Vazquez, Delia ^e   Marcus, Sheila ^d   Djuric, Zora ^a   Vahratian, Anjel ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

^c Integrated Health Associates   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; DOCOSAHEXAENOIC ACID; FISH OIL; ICOSAPENTAENOIC ACID; INTERLEUKIN 1BETA; INTERLEUKIN 6; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; FEMALE; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; MATERNAL PLASMA; MENTAL HEALTH; NUTRITIONAL ASSESSMENT; PREGNANCY OUTCOME; PREGNANT WOMAN; PROSPECTIVE STUDY; PUERPERAL DEPRESSION; PUERPERIUM; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT; TREATMENT RESPONSE; UMBILICAL CORD BLOOD; BLOOD; CLINICAL TRIAL; DIET THERAPY; FETUS BLOOD; MAJOR DEPRESSION; METABOLISM; PREGNANCY;

ANTIDEPRESSIVE AGENTS; DEPRESSION, POSTPARTUM; DEPRESSIVE DISORDER, MAJOR; DIETARY SUPPLEMENTS; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; EICOSAPENTAENOIC ACID; FEMALE; FETAL BLOOD; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; PREGNANCY; PREGNANCY OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79959338004     PISSN: None     EISSN: 14712393     Source Type: Journal    
DOI: 10.1186/1471-2393-11-46     Document Type: Article

References (44)

1. Kessler R, Berglund P, Demler O, Jin R, Koretz D, Merikangas K, et al. The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003, 289:3095-3105. 10.1001/jama.289.23.3095, 12813115.
2. Epidemiology, pathogenesis, and neurobiology of depression. , http://www.uptodate.com/contents/epidemiology-pathogenesis-and-neurobiology-of-depression?source=see_link
3. Stewart W, Ricci J, Chee E, Hahn S, Morganstein D. Cost of lost productive work time among US workers with depression. JAMA 2003, 289:3135-3144. 10.1001/jama.289.23.3135, 12813119.
4. Murray C, Lopez A. Alternative projections of mortality and disability by cause 1990-2020: Global burden of disease study. Lancet 1997, 349:1498-1504. 10.1016/S0140-6736(96)07492-2, 9167458.
5. Lopez A, Mathers C, Ezzati M, Jamison D, Murray CJL. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006, 367:1747-1757. 10.1016/S0140-6736(06)68770-9, 16731270.
6. Yonkers K, Ramin S, Rush J, Navarrete C, Carmody T, March D, Heartwell S, Leveno K. Onset and persistence of postpartum depression in an inner-city maternal health clinic system. Am J Psychiatry 2001, 158:1856-1863. 10.1176/appi.ajp.158.11.1856, 11691692.
7. Hibbeln J. Seafood consumption, the DHA content of mothers' milk and prevalence rates of postpartum depression: A cross-national, ecological analysis. J Affect Disord 2002, 69:15-29. 10.1016/S0165-0327(01)00374-3, 12103448.
8. Evans J, Heron J, Francomb H, Oke S, Golding J. Cohort study of depressed mood during pregnancy and after childbirth. BMJ 2001, 323:257-260. 10.1136/bmj.323.7307.257, 35345, 11485953.
9. Bennett H, Einarson A, Taddio A, Koren G, Einarson T. Prevalence of depression during pregnancy: Systematic review. Obstet Gynecol 2004, 103:698-709. 10.1097/01.AOG.0000116689.75396.5f, 15051562.
10. Flynn H, Blow F, Marcus S. Rates and predictors of depression treatment among pregnant women in hospital-affiliated obstetrics practices. Gen Hosp Pyschiatry 2006, 28:289-295.
11. Marangell L, Martinez J, Zboyan H, Chong H, Puryear L. Omega-3 fatty acids for the prevention of postpartum depression: Negative data from a preliminary, open-label pilot study. Depress Anxiety 2004, 19:20-23. 10.1002/da.10148, 14978781.
12. Cripe S, Frederick I, Qiu C, Williams M. Risk of preterm delivery and hypertensive disorders of pregnancy in relation to maternal co-morbid mood and migraine disorders during pregnancy. Paediatric and perinatal epidemiology 2011, 25:116-123. 10.1111/j.1365-3016.2010.01182.x, 21281324.
13. Grace S, Evindar A, Stewart D. The effect of postpartum depression on child cognitive development and behavior: A review and critical analysis of the literature. Arch Womens Ment Health 2003, 6:263-274. 10.1007/s00737-003-0024-6, 14628179.
14. Alwan S, Reefhuis J, Rasmussen S, Friedman J. Patterns of antidepressant medication use among pregnant women in a United States population. Journal of clinical pharmacology 2011, 51:264-270. 10.1177/0091270010373928, 20663997.
15. Kornum JB, Nielsen RB, Pedersen L, Mortensen PB, Norgaard M. Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis. Clinical Epidemiology 2010, 2:29-36. 2943182, 20865100.
16. Hendrick V, Stowe Z, Altshuler L, Hwang S, Lee E, Haynes D. Placental passage of antidepressant medications. Am J Psychiatry 2003, 160:993-996. 10.1176/appi.ajp.160.5.993, 12727706.
17. Zeskind P, Stephens L. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 2004, 113:368-375. 10.1542/peds.113.2.368, 14754951.
18. Oberlander T, Eckstein Grunau R, Fitzgerald C, Ellwood A, Misri S, Rurak D, et al. Prolonged prenatal psychotropic medication exposure alters neonatal acute pain response. Pediatr Res 2002, 51:443-453. 10.1203/00006450-200204000-00008, 11919328.
19. Casper R, Fleisher B, Lee-Ancajas J, Gilles A, Gaylor E, DeBattista A, et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 2003, 142:402-408. 10.1067/mpd.2003.139, 12712058.
20. Lattimore K, Donn S, Kaciroti N, Kemper A, Neal C, Vazquez D. Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: A meta-analysis. J Perinatol 2005, 25:595-604. 10.1038/sj.jp.7211352, 16015372.
21. Sanz E, De-las-Cuevas C, Kiuru A, Bate A, Edwards R. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: A database analysis. Lancet 2005, 365:482-487.
22. Ruchkin V, Martin A. SSRIs and the developing brain. Lancet 2005, 365:451-453.
23. Freeman MP, Hibbeln JR, Wisner KL, Davis JM, Mischoulon D, Peet M, Keck PE, Marangell LB, Richardson AJ, Lake J, Stoll AL. Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry. Journal of Clinical Psychiatry 2006, 67:1954-1967. 10.4088/JCP.v67n1217, 17194275.
24. Appleton KM, Hayward RC, Gunnell D, Peters TJ, Rogers PJ, Kessler D, Ness AR. Effects of n-3 long-chain polyunsaturated fatty acids on depressed mood: systematic review of published trials. Am J Clin Nutr 2006, 84:1308-1316.
25. Lin PY, Su KP. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. The journal of clinical psychiatry 2007, 68:1056-1061. 10.4088/JCP.v68n0712, 17685742.
26. Appleton K, Rogers P, Ness A. Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood. The American journal of clinical nutrition 2010, 91:757-770. 10.3945/ajcn.2009.28313, 20130098.
27. Jans LAW, Giltay E, Van der Does AJW. The efficacy of n-3 fatty acids DHA and EPA (fish oil) for perinatal depression. British journal of nutrition 2010, 104:1577-1585. 10.1017/S0007114510004125, 21078211.
28. Makrides M, Gibson R, McPhee A, Yelland L, Quinlivan J, Ryan P. Effect of DHA supplementation during pregnancy on maternal depression and neurodevelopment of young children: a randomized controlled trial. JAMA (Chicago, Ill) 2010, 304:1675-1683.
29. Ross BM, Seguin J, Sieswerda LE. Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid?. [Review] [116 refs]. Lipids in Health & Disease 2007, 6.
30. Martins J. EPA but not DHA appears to be responsible for the efficacy of omega-3 long chain polyunsaturated fatty acid supplementation in depression: evidence from a meta-analysis of randomized controlled trials. Journal of the American College of Nutrition 2009, 28:525-542.
31. Navarro P, Ascaso C, Garcia-Esteve L, Aguado J, Torres A, Martin-Santos R. Postnatal psychiatric morbidity: a validation study of the GHQ-12 and the EPDS as screening tools. General Hospital Psychiatry 2007, 29:1-7. 10.1016/j.genhosppsych.2006.10.004, 17189737.
32. Matthey S. Calculating clinically significant change in postnatal depression studies using the Edinburgh Postnatal Depression Scale. Journal of Affective Disorders 2004, 78:269-272. 10.1016/S0165-0327(02)00313-0, 15013253.
33. Eberhard-Gran M, Eskild A, Tambs K, Opjordsmoen S, Samuelsen SO. Review of validation studies of the Edinburgh Postnatal Depression Scale. Acta Psychiatrica Scandinavica 2001, 104:243-249. 10.1034/j.1600-0447.2001.00187.x, 11722298.
34. Jardri R, Pelta J, Maron M, Thomas P, Delion P, Codaccioni X, Goudemand M. Predictive validation study of the Edinburgh Postnatal Depression Scale in the first week after delivery and risk analysis for postnatal depression. Journal of affective disorders 2006, 93:169-176. 10.1016/j.jad.2006.03.009, 16644021.
35. Beck A, Ward C, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961, 4:561-571.
36. Beck CT, Gable RK. Comparative Analysis of the Performance of the Postpartum Depression Screening Scale With Two Other Depression Instruments. [Article]. Nursing Research 2001, 50(4):242-250. 10.1097/00006199-200107000-00008, 11480533.
37. Holcomb W, Stone L, Lustman P, Gavard J, Mostello D. Screening for depression in pregnancy: Characteristics of the Beck Depression Inventory. Obstet Gynecol 1996, 88:1021-1025. 10.1016/S0029-7844(96)00329-8, 8942846.
38. Steer R, Scholl T, Beck A. Revised Beck Depression Inventory scores of inner-city adolescents: Pre- and postpartum. Psychol Rep 1990, 66:315-320. 10.2466/PR0.66.1.315-320, 2326421.
39. Steer R, Scholl T, Hediger M, Fischer R. Self-reported depression and negative pregnancy outcomes. J Clin Epidemiol 1992, 45:1093-1099. 10.1016/0895-4356(92)90149-H, 1474405.
40. Beck A, Steer R, Garbin M. Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. Clin Psychol Rev 1988, 8:77-100.
41. Freeman M, Hibbeln J, Wisner K, Watchman M, Gelenberg A. An open trial of Omega-3 fatty acids for depression in pregnancy. Acta Neuropsychiatrica 2006, 18:21-24.
42. Freeman M, Hibbeln J, Wisner K, Brumbach B, Watchman M, Gelenberg A. Randomized dose-ranging pilot trial of omega-3 fatty acids for postpartum depression. Acta Psychiatr Scand 2005, 1-5.
43. Peet M, Horrobin DF. A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 2002, 59:913-919. 10.1001/archpsyc.59.10.913, 12365878.
44. Berto P, D'Ilario D, Ruffo P, Di Virgilio R, Rizzo F. Depression: Cost-of-illness studies in the international literature, a review. J Ment Health Policy Econ 2000, 3:3-10. 10.1002/1099-176X(200003)3:1<3::AID-MHP68>3.0.CO;2-H, 11967432.